Pages Menu
TwitterRssFacebook
ISSN (Online): 2454-1680

OncoExpert

INTERNATIONAL JOURNAL OF INTEGRATED ONCOLOGY

An Official Publication Of Society Of Pharmaceutical Science & Research
Categories Menu

Most Cited

 
Title
Views
PDF
Cited
3.

PRIMARY RENAL LYMPHOMA: A RARE CASE REPORT

Primary renal Non-hodgkin lymphoma is rare. Most of the cases are unilateral though bilateral cases have been reported. Extrarenal involvement is to be excluded by imaging/ staging laprotomy for definitive diagnosis. We are presenting a case of 40-year-old Indian female who was attended with history of right flank pain for 3 years, found to have right renal mass on CT scan, underwent right radical nephrectomy and six courses of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) regimen subsequent to histo-pathological confirmation. Patient is asymptomatic on follow up of 18...

Mukesh Kumar, Paramjeet Kaur, Yashpal Verma, Anil Khurana, Nupur Bansal, Ashok K Chauhan

Department of Radiotherapy, Pt. BDS PGIMS Rohtak INDIA

DOI:

16-19

1271

409

0

3.

ROLE OF COENZYME Q10 IN CURRENT ONCOLOGY PRACTICE: SUBSTANCE OR SHADOW!

CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10 efficacy.. Oral CoQ10 administration can correct CoQ10 deficiency since it increases CoQ10 tissue levels. CoQ10 therapy has no serious side effects in humans and new formulations have been developed that increase CoQ10 absorption and tissue distribution. CoQ10 has a role in carcinoma breast, cervix, lung, prostate, melanoma, cancer chemotherapy and cancer related fatigue. Future trends involving CoQ10 in many cancers needs more clinical trials for better understanding of CoQ10...

Abhishek Soni, Monica Verma, Sumeet Aggarwal, Vivek Kaushal and Yashpal Verma

Dr Abhishek Soni, Senior Resident, Department of Radiotherapy, Post-graduate Institute Of Medical Sciences, Rohtak (INDIA) - 124001

DOI:

14-22

1559

1094

0

2.

PAPILLARY THYROID MICROCARCINOMA IN A BENIGN THYROID NODULE: AN UNDERDIAGNOSED ENTITY

ABSTRACT Fine needle aspiration cytology, though, is a reliable, minimally invasive procedure with high sensitivity, specificity and diagnostic accuracy, still it has its limitations in making out diagnosis of thyroid nodules. Here we present an uncommon case of 52 years old Indian female with complaint of mass on antero-medial aspect neck. Fine needle aspiration cytology was suggestive of colloidal goiter. For cosmetic indication, thyroidectomy was done and histopathological examination sought to confirm the cytological diagnosis. The incidental finding was uncommon, revealing papillary thyroid microcarcinoma. Worth emphasizing is the possibility of uncommon malignant disease like thyroid microcarcinoma, in view of limitations of fine needle aspiration cytology in apparently benign thyroid...

Sumiti Gupta, Neha Singh, Shiwani Malik, Rajnish Kalra, Rajiv Sen

Dr Neha singh Senior Resident, Department of Pathology, Pt. B.D.Sharma Postgraduate Institute of Medical Sciences, Rohtak (INDIA)

DOI:

10-13

1349

437

0

4.

CHEMOTHERAPY INDUCED NEUROPATHY: PATHO-PHYSIOLOGY AND POSSIBLE NEURO-PROTECTIVE STRATEGIES

With the advent of effective and intensive chemotherapy, we are able to achieve better response rates as well as improved survival but the side effects remain a constraint. This article intends to discuss one of the side effects of chemotherapy i.e. neuropathy; culprit agents, mechanism and therapeutic strategies to manage it.

Ramesh Sabharwal, Ravi Uniyal, Yashpal Verma and Mukesh Kumar Bharti

Dr. Ramesh Sabharwal Medical Officer, General Hospital, Department of Health, Kurukshetra, Haryana (India)

DOI:

23-30

1769

614

0

2.

ROLE OF PHYSIOTHERAPY IN PREVENTION AND MANAGEMENT OF LYMPHEDEMA IN POST-OPERATIVE BREAST CANCER PATIENTS

After surgery for breast cancer, the most common postoperative complication is secondary lymphedema which may sometimes be more challenging to manage than the disease itself. This systematic literature review aims to highlight the role of physiotherapy in management of secondary lymphedema in post-operative patients of breast cancer and its current status. The literature review has been conducted using available textbooks and online database of PubMed, Medline, SciELO, LILACS (Latin American and Caribbean Literature) and EMBASE. Online search has been made through English literature mainly, from 1990 to 2015 and focused on research or review articles. Review found physiotherapy; with appropriate combination of techniques, started early; has been very effective in prevention and management of lymphedema in post-operative breast cancer...

Savarna, Davinder Kumar, Kumar Pritam, Preeti Manocha, Dimple Choudhary

Dr Savarna Department of Orthopedics, Pt. B.D. Sharma University of Health Sciences,Rohtak (INDIA)124001

DOI:

11-15

1480

457

0

7.

CONCOMITANT CHEMORADIATION IN HEAD AND NECK CANCER: ROLE OF 5-FU ANALOGS.

Head and neck cancer forms the major chunk of cancer patients in developing country like India. About 2/3rd of the patients present in locally advanced stage in which the cure rates are low. Concomitant chemoradiation with platinum compounds is the standard treatment for such patients as it offers organ and function preservation with better quality of life. MACH-NC update (2009) shows that concomitant chemoradiation provides an absolute survival benefit of 6.5% at 5 years. Many chemotherapeutic agents including 5-FU, taxanes and biologically targeted therapy have been investigated in an effort to maximize the locoregional and survival in locally advanced head and neck cancer. Oral chemotherapeutic agent gives the ease of self medication on daily basis without the need for hospital admission and intravenous infusion. Theoretically daily administration of oral chemotherapy agent mimics the continous infusion of a parenteral agent. Since infusional 5-FU along with Radical RT has achieved a complete response rate of 68% for 5-FU arm versus 56% for placebo arm (p=0.04) with the overall median survival of 33 months for 5-FU versus 25 months for placebo arm, Capecitabine (analog of 5-FU) in low doses have been used in concomitant setting for locally advanced head and neck cancer. Overall response rate observed has been 33-89% with manageable toxicity and near total patient compliance. The maximally tolerated dose to be given daily during radiation therapy is 500 mg/m2 b.i.d. Lower dose doses of 250-350 mg/m2 have also been used in concomitant with lesser toxicity and greater...

Kailash Mittal, Anil Kumar Dhull, Rajeev Atri, Rakesh Dhankhar, Vivek Kaushal

Dr. Kailash Mittal, Assistant Professor, Department of Radiotherapy, UPRIMS&R, Saifai, Etawah (U.P.) INDIA

DOI:

35-46

1472

16

0

1.

PALLIATIVE CHEMORADIOTHERAPY VERSUS RADIOTHERAPY ALONE FOR MANAGEMENT OF LOCALLY ADVANCED HEAD & NECK CARCINOMA PATIENTS WITH POOR PERFORMANCE STATUS

Introduction: Palliative external beam radiotherapy (EBRT) and chemotherapy is commonly practiced for management of locally advanced head & neck carcinoma (LAHNC) patients with poor performance status. This study compares EBRT alone and EBRT along with low dose Gemcitabine. Method: Study was conducted in Department of Radiotherapy, PGIMS Rohtak, in 2008-09; on histopathologically proven, untreated 60 cases of LAHNC, having KPS 60-70. Patients were randomly assigned either control group (n=30), given EBRT alone as 20Gy/5Fr/5days or study group (n=30), given EBRT as 20Gy/ 5Fr/ 5days and Gemcitabine 200 mg/m2 i.v. 2 hour prior to radiotherapy on day 1. Mean age was 53 years (26-84 years). Male:female ratio was 5:1. Most common primary site was base of tongue followed by larynx. Major symptoms were pain, difficulty in swallowing and altered voice. Patients were staged as per AJCC 2002; 2/3rd were stage IVA and 1/3rd were IVB. Despite randomization, there was no significant difference between two groups in age, sex, primary site, stage, and performance status. The side effects were graded as per RTOG criteria. Results: Objective response, 3 months post-treatment, in the chemoradiotherapy and radiotherapy alone group respectively was: CR 7% vs 0%; PR 30% vs 33%; stable disease 56% vs 46% and progressive disease 7% vs 20%. Subjective response, similarly was better in study group through out; even significantly better in dysphagia at 3 months follow up. Acute skin reactions were: Grade I- 73% vs 47% at 2 weeks and 60% vs 40% at 1 month respectively. Acute mucosal reactions were: Grade I- 30% vs 17%, Grade II- 43% vs 17% respectively. No hematological and grade III/IV skin or mucosal reactions observed. Differences in reactions were not statistically significant. Conclusion: In management of LAHNC patients with poor performance status, addition of low dose Gemcitabine to palliative radiotherapy gives better disease control and symptomatic relief without unmanageable side...

Dinesh Ranga, Yashpal Verma, Ashok K. Chauhan, Ramesh Sabharwal, Mukesh Bharti

Dr Yashpal Verma, Medical Officer, Department of Radiotherapy, Post-graduate institute of medical sciences, Rohtak (INDIA).

DOI:

01-09

1153

480

0

8.

TARGETING IMMUNITY TO TREAT CANCERS- A BRIEF REVIEW

Cancer cells have a multitude of mechanisms to avoid and suppress immunity. Normal cells when exposed to chemical carcinogens, irradiation and certain viruses get transformed to cancer cells which can grow indefinitely. These cells have decreased requirements for growth factors; do not undergo apoptosis resulting in malignancy. The tumor cells have various antigens which are responsible for the generation of immune responses towards that particular tumor. There are two types of tumor antigens; tumors specific transplantation antigens (TSTAs) and tumor associated transplantation antigens (TATAs). The TSTAs are specific to tumor, result from mutations which alter the cellular proteins while TATAs may be proteins present in or during some stages of fetal development but not expressed or expressed at low levels in normal adult cells. Adoptive T-cell therapy involves the ex vivo cultivation of T cells with activity against a specific target cancer antigen to increase the frequency of these T cells to achieve therapeutic levels and then infuse them back into the patient. Oncolytic viruses selectively infect, replicate in, and kill tumor cells with no or limited impact on normal tissues which means that tumor cells have surface receptors to bind the virus. Monoclonal antibodies (mAbs) are immunoglobulins derived from a single clone of B cells, act by targeting an antigen which acts a ligand of receptor involved in signal transduction within the...

Nidhi Tejan, Varsha Gupta

Dr. Nidhi Tejan, Senior Resident, Department of Microbiology, SGPGI, Luknow, INDIA

DOI:

47-55

1524

848

0

1.

PRIMARY LEIOMYOSARCOMA OF TESTIS: A RARE TESTICULAR TUMOUR WITH BETTER OUTCOME

ABSTRACT Aim of the Study: To review and suggest treatment approach for rare diseases Leiomyosarcoma of testis. Material and Method: Here, we have reviewed management of Primary Leiomyosarcoma of the testis by search of case reports in PubMed Central, Embase, Cochrane, and Web of Science Central database. We have classified the obtained information as per Oxford Centre for Evidence Based Medicine (OCEBM) level of evidence, and National Comprehensive Cancer Network (NCCN) Categories of Evidence and Consensus. Here, current treatment scenario for sarcoma and its outcome will be discussed for a new case of low grade primary leiomyosarcoma of testis that was confirmed with Immuno-histochemistry after high inguinal orchidectomy, for painless testicular mass. Systematic review, line listing of old reported cases and treatment evidences were analysed by reviewing various international databases. Results: Leiomyosarcoma is a very rare disease, and only few cases have been reported on online databases. It is usually reported among elderly men following irradiation or long-term anabolic steroid use. Intensive search reveals lack of definitive guidelines for management of leiomyosarcoma because available evidence is level V as per OCEBM and level C as per NCCN. Conclusion: Even though early diagnosis and treatment by high inguinal orchidectomy improves survival and decreases risk of recurrence of leiomyosarcoma, there is need of research and definitive chemotherapy guidelines, similar to sarcoma of other site of the...

Divyesh S. Rana, Vimal D. Batra, Chirag B. Mistry, Anil K. Goela

Dr. Divyesh Rana, Department of Radiotherapy, Medical College and SSG Hospital Baroda, Sayajigunj, Vadodara, Gujrat, India

DOI:

01-09

1492

484

0

9.

UNVEILING THE MYSTERIOUS WORLD OF SALIVARY DUCT CARCINOMA OF THE PAROTID GLAND- A RARE CASE REPORT AND REVIEW OF THE LITERATURE.

Among many variants of salivary gland tumors, salivary duct carcinoma (SDC) of the parotid gland is a highly aggressive and rare malignant tumor which ranks among those with the worst prognosis and a significant mortality. These tumors got their name based on its microscopic resemblance and being analogous to similar schemes in the ductal carcinoma of the breast. The characteristic microscopic features of salivary duct carcinoma are composed of comedo necrosis, a cribriform and papillary pattern of intraductal growth and aggressive infiltration to adjacent structures. Majority of cases are typically treated with radical parotidectomy with or without neck dissection followed by adjuvant radiotherapy. We present a case of a 60 year old male patient who presented with progressive facial paralysis and right parotid swelling. FNAC was positive for malignancy. PET-CT showed a lesion in right superficial lobe of parotid with bilateral neck nodes. Patient underwent right total parotidectomy with right radical neck dissection and left modified neck dissection. Facial nerve was preserved. Microscopic examination reported it as a salivary duct carcinoma, positive for Her2/neu antibody with lymph node metastasis (22/23). Patient received adjuvant radiotherapy and 12 cycles of Transtuzumab. There were no recurrences or metastases within 12 months of...

Irfan Bashir, Sunny Jain, Anil Thakwani, Anshul Bhatnagar, Kundan S. Chufal.

Dr. Irfan Bashir. Batra Cancer Centre, Batra Hospital and Medical Research Centre, 1 Tughlaqabad Institutional Area, M. B. Road, New Delhi, India.

DOI:

56-61

975

799

0

Page 1 of 3123